SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk Patients

SAN DIEGO, March 15, 2015 -- Edwards Lifesciences Corporation (EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that 30-day outcomes for high- and intermediate-risk patients treated with the SAPIEN 3 transcatheter aortic valve demonstrated the lowest all-cause mortality rates of any of the PARTNER studies, as well as excellent clinical outcomes on the other components of the primary endpoint measures of stroke and paravalvular regurgitation.  This first report of SAPIEN 3 data in the United States, and first report on intermediate risk transcatheter aortic valve replacement (TAVR) patients, was presented as part of the late-breaking clinical trials at the American College of Cardiology's (ACC) 64th Annual Scientific Session in San Diego.

Bacterin Announces Distribution Agreement With Spartan Medical for DOD and VA Medical Centers

BELGRADE, Mont., March 10, 2015 -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material, today announced it has signed a national distribution agreement with Spartan Medical, Inc., a service-disabled, veteran-owned, small business focused on distribution to government medical facilities.

Under the agreement, Spartan Medical will distribute Bacterin's proprietary product portfolio to the medical centers affiliated with the US Department of Defense (DOD) and the US Department of Veteran's Affairs (VA). Spartan Medical is an established distribution entity that provides best-in-class products and services to its customers, with specific experience in orthopedic and biologics distribution, and government contracting.

Second Sight Announces Successful First Implants of the Argus® II Retinal Prosthesis System at Two New Centers in Italy

SYLMAR, Calif. -- Second Sight Medical Products, Inc. (Nasdaq: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that two newly approved centers, located in Camposampiero and Florence, have successfully completed their first commercial implants of the Argus II Retinal Prosthesis System (“Argus II”) in patients with outer retinal degeneration.

“We are thrilled to see the expanded availability of Argus II in Italy,” stated Dr. Robert Greenberg, Chief Executive Officer of Second Sight. “By offering Argus II in Italy, we are able to provide patients with outer retinal degeneration the chance to lead more independent lives, which can be life changing for these patients.”

TSO3 enters into first commercial agreement for STERIZONE® VP4 Sterilizer

QUÉBEC, March 6, 2015 - TSO3 Inc. (TOS.TO) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has signed its first commercial agreement with Getinge Infection Control in support of the launch of the STERIZONE® VP4 Sterilization System. The non-exclusive agreement covers multiple markets in which Getinge has significant market share, including North America and other selected markets. Efforts to launch the product will begin immediately.

Cyberonics Reports Fiscal 2015 Third Quarter Results

CE Mark approval of VITARIA™ generator for CHF ----- U.S. revenue growth of 9% to $58m ---- Continued strong earnings growth

HOUSTON, Feb. 26, 2015 - Cyberonics, Inc. (CYBX) today announced results for the quarter ended January 23, 2015.

Quarterly highlights1

Operating results for the third quarter of fiscal 2015 compared to the third quarter of fiscal 2014 and other achievements include:

  • Worldwide net sales of $72.1 million, an increase of 9% on an adjusted basis;
  • U.S. net sales reached $57.6 million, an increase of 9%, with units increasing by 6%;

Videos / Webinars

View all videos

Stockjunction Members

View All Members